Kaiser wins $142 mil­lion in law­suit against Pfizer

Modern Healthcare - - Late News -

A fed­eral jury in Bos­ton awarded Kaiser Per­ma­nente $142 mil­lion in a law­suit against Pfizer tar­get­ing off-la­bel mar­ket­ing of the epilepsy drug Neu­ron­tin by Warner-Lam­bert Co., which Pfizer ac­quired in 2000. The com­plaint al­leged that Warner-Lam­bert cre­ated ac­cep­tance of the drug for a va­ri­ety of un­ap­proved uses by host­ing sem­i­nars for physi­cians and ghost­writ­ing ar­ti­cles signed by physi­cians paid to lend their names. “As a re­sult, we ul­ti­mately spent more than $100 mil­lion on a very ex­pen­sive drug that we now know is no more ef­fec­tive than a placebo for pain, bipo­lar and many other con­di­tions it was pro­moted to re­lieve,” Kaiser said in a writ­ten state­ment. Pfizer plans to ap­peal the ver­dict, which came af­ter a 21-day trial and af­firmed Kaiser’s claims that the tac­tics vi­o­lated the fed­eral rack­e­teer­ing statute and con­sti­tuted fraud­u­lent busi­ness acts un­der Cal­i­for­nia law.

Newspapers in English

Newspapers from USA

© PressReader. All rights reserved.